期刊文献+

缬沙坦美托拉宗片溶出度检测的方法学研究

Methodological validation of the dissolution test of valsartan and metolazone tablets
下载PDF
导出
摘要 目的建立缬沙坦美托拉宗片溶出度测定方法,并进行方法学验证,为药品的质量控制提供保障。方法采用高效液相色谱法,色谱柱为Agilent SB C18(4.6 mm×250 mm,5μm)色谱柱,流动相为乙腈-水(磷酸调p H值至2.3,比例50∶50),流速1.0 ml/min,检测波长235 nm。结果缬沙坦在6~120μg/ml浓度范围内线性关系良好(r=1.0000,n=6),美托拉宗在37.5~750 ng/ml浓度范围内线性关系良好(r=1.0000,n=6);缬沙坦和美托拉宗的平均回收率分别为99.85%和99.44%,RSD分别为1.05%和1.16%,溶液在24 h内稳定,滤膜对两种药物均没有吸附,两种药物的重复性及中间精密度的相对标准偏差(RSD)均〈2%。结论建立的溶出度检测方法操作简单,灵敏度及准确度高,满足缬沙坦美托拉宗片质量控制的要求。 Objective To establish a method for testing the dissolution of valsartan and metolazone tablets,and validate the method to provide a basis for drug quality control. Methods The dissolution was analyzed by HPLC method. An Agilent SB C18(4.6mm×250 mm,5 μm)column and a mixture of acetonitrile and water were used with the ratio of 50∶50 at a flow rate of 1.0 ml/min with UV detection at 235 nm. Results The calibration curve of valsartan and metolazone was 6-120 μg/ml(r=1.0000,n=6)and 37.5-750ng/ml(r=1.0000,n=6),respectively. The average recovery of the two drugs was 99.85% and 99.44% with RSD of 1.05% and 1.16%(n=9),respectively.The test solution was stable within 24 h and the filter did not interfere with determination as the two drugs were not adsorbed on it.RSD of this method were all less than 2%. Conclusion The method is simple,sensitive,accurate,and with highly distinguished ability for quality control.
出处 《国际药学研究杂志》 CAS CSCD 北大核心 2016年第2期387-391,共5页 Journal of International Pharmaceutical Research
基金 国家“重大新药创制”科技重大专项资助项目(2012ZX09301003-001-009)
关键词 高效液相色谱 缬沙坦 美托拉宗 溶出度 HPLC valsartan metolazone dissolution
  • 相关文献

参考文献12

  • 1Wagner J,Drab M,Bohlender J, et al. Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain[J].Clin Exp Hypertens, 1998, 20(2): 205-221.
  • 2刘力生.中国高血压防治指南2010[J].中国医学前沿杂志(电子版),2011,3(5):42-93. 被引量:1220
  • 3The United States Pharmacopeial Convention. USP35-NF30(美国药典35版-国家处方集30版) [S]. Offical Monographs, 2011:5556,5971-5972.
  • 4贾孟良,谢守霞,杨红英,练宏新,王玉.国内外不同厂家缬沙坦胶囊在多种溶出介质中溶出曲线的比较[J].中国医院药学杂志,2012,32(22):1800-1803. 被引量:4
  • 5国家药典委员会 . 中国药典2015年版 [S]. 北京:中国医药科技出版社,2015:325、375.
  • 6Curry CL,Janda SM,Harris R, et al. Clinical studies of a new, low-dose formulation of metolazone for the treatment of hypertension[J].Clin Ther, 1986, 9(1): 47-62.
  • 7Sica DA. Metolazone and its role in edema management[J].Congest Heart Fail, 2003, 9(2): 100-105.
  • 8Kr?ger N,Szuba J,Frenzel H. Metolazone in the treatment of advanced therapy-resistant dilated cardiomyopathy[J].Med Klin (Munich), 1991, 86(6): 305-308, 332.
  • 9Pilewski RM,Scheib ET,Misage JR, et al. Technique of controlled drug assay in hypertension. Ⅴ. Comparison of hydrochlorothiazide with a new quinethazone diuretic, metolazone[J].Clin Pharmacol Ther, 1971, 12(5): 843-848.
  • 10西安立邦肇新生物科技有限公司. 一种复方降压制剂及其应用:中国,CN104324377A [P]. 2015-02-04.

二级参考文献28

共引文献1222

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部